Resposta do capim-elefante (Pennisetum purpureum, Schum) a nitrogênio, fósforo e potássio em Tracuateua e Benevides, estado do Pará.

v.5 Pastagem e produção animal

Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®)

Recurrent respiratory papillomatosis (RRP) is caused by a human papilloma virus (HPV). It is a rare, sometimes debilitating disease compromising voice and airway. RRP is characterized by a variable course of disease, potentially leading to frequent annual surgical procedures, the number of which may exceed a hundred during the life time. The therapy focuses on surgical removal of the mucosal lesions in order to keep the airway open and the voice satisfactory. Till now, there is no curative therapy for the virus infection in itself. As recurrent surgery alone has proven to be insufficient in many cases, adjuvant therapy is increasingly being used. One of the mainstays of adjuvant therapy is the administration of intralesional cidofovir (Vistide Ò). Cidofovir is an antiviral agent, registered for the treatment of cytomegalovirus (CMV) retinitis in patients wit

Recurrent respiratory papillomatosis: From diagnosis to treatment

Recurrent respiratory papillomatosis (RRP) is a rare, benign, recurrent disease of the airway. Its warty lesions are associated with the Human papilloma virus (HPV) types 6 and 11, with a predisposition in the larynx. Because no curative treatment exists, some patients may require more than 100 surgical interventions. The primary aim of treatment is to prevent dyspnea and to minimize voice complaints. This thesis presents five studies on the diagnosis, clinical course, treatment, and the quality of life. The section on diagnosis shows that "Narrow band imaging" (NBI), a visualization technique to distinguish between healthy and unhealthy tissue, is simple, safe and fast in its use, and visualizes papillomata better during the operation, allowing for a better removal of the lesions. The section on clinical course shows differences in disease severity between RRP associated with HPV6 on the one hand, and HPV11 on the other hand. The section on treatment examines the side effects of a commonly used antiviral agent against HPV in RRP patients, and the immune response after therapeutic HPV vaccination in RRP patients. The last section investigates the impact on the voice of surgical intervention, and finds an improvement in voice-related problems after surgery. On the basis of the findings in this thesis, the RRP patient can be provided with a better understanding of the disease, and on the future prospects of this debilitating disease

Does symptom reduction after cognitive behavioural therapy of anxiety disordered patients predict personality change?

Item does not contain fulltextFor decades, personality was thought to be a set of stable characteristics However, in the dimensional approach, personality traits are considered to vary on a continuum This retrospective cohort study examines changes in personality traits, as measured by the NEO Five Factor Inventory, in anxiety-disordered inpatients Paired sample T-test analyses are used to measure trait differences before and after treatment Analyses of variance are applied to measure the influence of diagnosis on personality change, and regression analyses to investigate if the 90-item symptom checklist symptom reduction predicts personality trait changes Results show that patients become less neurotic and more extravert at post-measurement, supported by large to medium effect sizes, and are not influenced by diagnostic category Only 30% and 21% of the change in neuroticism and extraversion respectively, is explained by symptom reduction It is concluded that personality traits neuroticism and extraversion can change over time in anxious inpatients while changes are not a direct consequence of a mood-state effect (symptom reduction) Results are compatible with a dimensional conceptualization of psychopathology, which will be incorporated in the future edition of the Diagnostic and Statistical Manual for Mental Disorders (DSM-V)

Change of Voice Handicap Index after treatment of benign laryngeal disorders

Voice disorders can have major impact on quality of life. Problems caused by these disorders can be experienced in different domains. The Voice Handicap Index (VHI) is a well-known voice-related quality of life instrument to measure physical, emotional and functional complaints. VHI change after treatment in seven separate benign laryngeal disorders was studied. In addition, correlation between the three domains was examined. VHI forms were completed before and 3 months after treatment. In a 5-year-period, 143 patients with seven specific diagnoses were retrospectively included. VHI improved for six diagnoses polyp (p <0.000), cyst (p = 0.001), unilateral paralysis (p = 0.001), Reinke edema (p = 0.016), papillomatosis (p = 0.001), nodules (p = 0.002). Sulcus glottidis did not change (p = 0.897). Mean VHI after treatment was higher for females (p = 0.021). The values of the three domains correlate statistically significant. For each diagnosis, the mean VHI after treatment remained higher than in subjects with a healthy voice. Because the domains are interdependent, their absolute values could not be compared. After treatment, VHI improved in six of the seven diagnoses. The scores on the physical, emotional, and functional domain are interdependent. Scores of the different domains cannot be compared